Abstracts Archive - Page 1506 of 2425 - ACR Meeting Abstracts

Abstract Number: 1327 • 2016 ACR/ARHP Annual Meeting
Patients with Chikungunya Fever Have Increased Serum Levels of Proinflamatory Cytokines
Andrea Dantas¹, Claudia Marques², Nara Cavalcanti¹, Aline Ranzolin¹, Laurindo Rocha Jr³, Carolina Andrade¹, Paula Toche¹, Mariana Luna⁴, Kamila Vilar⁵, Pablo Cardoso⁶, Michelly Pereira⁷, Moacyr Rêgo⁷, Angela Duarte⁸ and Maira Pitta⁶, ¹Hospital das Clínicas, Universidade Federal de Pernambuco, Recife, Brazil, ²Hospital das Clínicas, Universidade Federal de Pernambuco, Recife - PE, Brazil, ³Rheumatology, Instituto de Medicina Integral Professor Fernando Figueira - IMIP, Recife, Brazil, ⁴Universidade Federal de Pernambuco, Recife, Brazil, ⁵Departamento de bioquímica, Laboratório de Imunomodulação e Novas Abordagens Terapêuticas - UFPE, Recife, Brazil, ⁶Departamento de Bioquímica, Laboratório de Imunomodulação e Novas Abordagens Terapêuticas - UFPE, Recife, Brazil, ⁷Bioquimica, Laboratório de Imunomodulação e Novas Abordagens Terapêuticas - UFPE, Recife, Brazil, ⁸Av. Prof. Moraes Rego, s/n, Av. Prof. Moraes Rego, s/n, Recife, Brazil
Background/Purpose: Chikungunya fever (CHIK) is an arboviral disease characterized by sudden onset of fever and incapacitating polyarthralgia. Some patients develop chronic articular symptoms but the…
Abstract Number: 1328 • 2016 ACR/ARHP Annual Meeting
Infective Endocarditis with Septic Arthritis: A Single-Center Experience
Sarah B. Lieber¹, Robert Shmerling², Andy Moore³, Mary Louise Fowler⁴, Kunwal Nasrullah⁵ and Ziv Paz¹, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA, ³Division of Rheumatology, Cambridge Health Alliance, Harvard Medical School, Boston, MA, ⁴Boston University School of Medicine, Boston, MA, ⁵Boston University Medical School, BOSTON, MA
Background/Purpose: Echocardiogram is frequently performed on patients presenting with septic arthritis (SA) but rarely demonstrates evidence of infective endocarditis (IE). Similarly, while patients with IE…
Abstract Number: 1329 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Biologics in Relapsing Polychondritis: A National Multicenter Study in France
Guillaume Moulis^1,2,3, Grégory Pugnet⁴, Nathalie Costedoat-Chalumeau⁵, Alexis Mathian⁶, Gaëlle Leroux⁷, Jonathan Boutemy⁸, Laurence Bouillet⁹, Sabine Berthier¹⁰, Jean Baptiste Gaultier¹¹, Pierre-Yves Jeandel¹², Amadou Konaté¹³, Arsène Mékinian¹⁴, Elisabeth Solau-Gervais¹⁵, Benjamin Terrier^16,17, Daniel Wendling¹⁸, Camille Garnier¹, Pascal Cathebras¹⁹, Laurent Arnaud²⁰, Patrice Cacoub⁷, Zahir Amoura⁶, Jean-Charles Piette⁷, Philippe Arlet²¹, Aurore Palmaro², Maryse Lapeyre-Mestre² and Laurent Sailler²², ¹Internal Medicine, Toulouse University Hospital, Toulouse, France, ²UMR 1027, INSERM-University of Toulouse, Toulouse, France, ³CIC 1436, Toiulouse, France, ⁴Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, INSERM UMR 1027, Toulouse, France, ⁵Cochin University Hospital, Internal Medicine, Paris, France, ⁶Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ⁷Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ⁸Department of Internal Medicine, Caen University Hospital, Caen, France, ⁹CHU, Grenoble, France, ¹⁰Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ¹¹Internal medicine, Saint Etienne, France, ¹²Internal Medicine, Nice University Hospital, Nice, France, ¹³Internal Medicine, Montpellier University Hospital, Montpellier, France, ¹⁴Service de médecine interne. Hôpital Saint-Antoine., Paris, France, ¹⁵Rheumatology Department, University Hospital, Poitiers, Poitiers, France, ¹⁶INSERM U1016, Institut Cochin, Equipe Neutrophiles et Vascularites, Paris, France, ¹⁷National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ¹⁸Service de Rhumatologie, CHU Jean Minjoz, Besancon, France, ¹⁹Internal Medicine, University Hospital St Etienne, St Etienne, France, ²⁰Inserm UMRS 1136, Paris, France, ²¹Service de Médecine Interne, CHU Purpan, Toulouse,, France, ²²Internal Medicine, Internal Medicine department, Toulouse University Hospital, Toulouse, France
Background/Purpose: No study has compared the efficacy and the safety of biologics in a large relapsing polychondritis (RP) cohort. This is the aim of the…
Abstract Number: 1330 • 2016 ACR/ARHP Annual Meeting
Clinical Presentations of Relapsing Polychondritis: More Than a Swollen Ear
Marcela Ferrada¹, Shubhasree D Choudhury², Kam Newman², Ninet Sinaii³, Monica Guma⁴, Thomas Christie⁵ and James D. Katz², ¹Critical Care, National Institutes of Health, Bethesda, MD, ²NIAMS, National Institutes of Health, Bethesda, MD, ³Clinical Center, National Institutes of Health, Bethesda, MD, ⁴Medicine, UCSD, La Jolla, CA, ⁵Relapsing Polychondritis Awareness and Support Foundation, Anoka, MN
Background/Purpose: Relapsing polychondritis (RP) is a rare and in some cases fatal autoimmune disease that can affect multiple organs including cartilaginous structures. The disease is…
Abstract Number: 1331 • 2016 ACR/ARHP Annual Meeting
Disease Patterns and Long Term Outcome Amongst Patients with Relapsing Polychondritis – Single Centre Experience
Chee Ken Cheah, Shirish Sangle (Joint First Author) and David D'Cruz, Louise Coote Lupus Unit, Guy's and St. Thomas' Hospital, London, United Kingdom
Background/Purpose: Relapsing polychondritis (RP) is a rare autoimmune disorder characterized by cartilage inflammation and damage. Chronic RP may lead to sequelae due to cartilage tissue…
Abstract Number: 1332 • 2016 ACR/ARHP Annual Meeting
Severe Complications and Immunosuppressive Treatments in 33 Patients with Relapsing Polychondritis
Toshiki Nakajima¹, Hajime Yoshifuji¹, Chikashi Terao², Kosaku Murakami¹, Nobuo Kuramoto¹, Ran Nakashima¹, Yoshitaka Imura³, Masao Tanaka¹, Koichiro Ohmura¹ and Tsuneyo Mimori¹, ¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Genomic Center, Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan, ³Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan
Background/Purpose: Since relapsing polychondritis (RP) is a rare disease as the prevalence rate is 0.0004% in Japan, its severe complications, prognosis and immunosuppressive therapies have…
Abstract Number: 1333 • 2016 ACR/ARHP Annual Meeting
Relevance of Granulomatous Presentation for the Diagnosis and Outcome of Uveitis: Retrospective Case-Control Study of 251 Patients
Jérôme Hadjadj¹, Thibault Chapron², Manal Assala¹, Sawsen Salah², Bertrand Dunogue¹, Matthieu Groh³, Philippe Blanche¹, Luc Mouthon⁴, Dominique Monnet², Claire Le Jeunne⁴, Antoine Brezin² and Benjamin Terrier³, ¹Internal Medicine, Cochin Hospital, Paris, France, ²Ophtalmology, Cochin Hospital, Paris, France, ³National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁴Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France
Background/Purpose: Findings of ophthalmologic examination can guide the diagnostic management of uveitis. Granulomatous presentation is commonly associated with peculiar causes, including infections, eye-restricted diseases, or…
Abstract Number: 1334 • 2016 ACR/ARHP Annual Meeting
Contribution of Diagnostic Investigations in the Management of Uveitis: Retrospective Analysis of 300 Patients
Jérôme Hadjadj¹, Thibault Chapron², Manal Assala¹, Sawsen Salah², Bertrand Dunogue¹, Matthieu Groh³, Philippe Blanche¹, Luc Mouthon⁴, Dominique Monnet², Claire Le Jeunne⁴, Antoine Brezin² and Benjamin Terrier³, ¹Internal Medicine, Cochin Hospital, Paris, France, ²Ophtalmology, Cochin Hospital, Paris, France, ³National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁴Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France
Background/Purpose: Uveitis represents a diagnostic and therapeutic challenge, as well as an economic one, due to its heterogeneous presentation, multiple underlying causes and lack of…
Abstract Number: 1335 • 2016 ACR/ARHP Annual Meeting
Long–Term Safety and Efficacy of Adalimumab in Patients with Non-Infectious Intermediate, Posterior, or Panuveitis in an Ongoing Open-Label Study
Eric B. Suhler¹, Glenn J. Jaffe², Quan Dong Nguyen³, Antoine P. Brezin⁴, Manfred Zierhut⁵, Albert Vitale⁶, Mirjam van Velthoven⁷, Alfredo Adan⁸, Lyndell Lim⁹, Michal Kramer¹⁰, Ariel Schlaen¹¹, Eric Fortin¹², Cristina Muccioli¹³, Hiroshi Goto¹⁴, Toshikatsu Kaburaki¹⁵, Anne Camez¹⁶, Alexandra P. Song¹⁷, Martina Kron¹⁶, Samir Tari¹⁷ and Andrew D. Dick¹⁸, ¹Oregon Health & Science University, Casey Eye Institute, and VA Portland Health Care System, Portland, OR, ²Duke University, Durham, NC, ³Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE, ⁴Université Paris Descartes, Hôpital Cochin, Paris, France, ⁵Center of Ophthalmology, University of Tuebingen, Tuebingen, Germany, ⁶University of Utah, Salt Lake City, UT, ⁷Rotterdam Eye Hospital, Rotterdam, Netherlands, ⁸Ophthalmology, Hospital Clinic de Barcelona,, Barcelona, Spain, ⁹Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia, ¹⁰Rabin Medical Center, Petach Tikva, Tel Aviv University, Tel Aviv, Israel, ¹¹Austral University, Buenos Aires, Argentina, ¹²University of Montreal, Montreal, QC, Canada, ¹³Federal University of São Paulo, São Paulo, Brazil, ¹⁴Tokyo Medical University, Tokyo, Japan, ¹⁵Ophthalmology, The University of Tokyo School of Medicine, Bunkyo-ku, Japan, ¹⁶Abbvie Deutschland GmbH & Co KG, Ludwigshafen, Germany, ¹⁷AbbVie Inc., North Chicago, IL, ¹⁸University of Bristol, Bristol Eye Hospital; National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital and University College London, Institute of Ophthalmology, London, United Kingdom
Background/Purpose: To evaluate the long-term safety and efficacy of adalimumab (Humira®) in patients with non-infectious intermediate, posterior, or panuveitis (NIPPU) in an open-label clinical trial…
Abstract Number: 1336 • 2016 ACR/ARHP Annual Meeting
Tocilizumab for Uveitic Cystoid Macular Edema Refractory to Other Synthetic and Biological Immunosuppressive Drugs. Multicenter Study of 25 Patients
Natalia Palmou-Fontana¹, Vanesa Calvo-Río¹, Marina Mesquida², Alfredo Adan³, M. Victoria Hernández⁴, Emma Beltran⁵, Elia Valls⁶, David Diaz-Valle⁷, Gisela Díaz-Cordovés⁸, Marisa Hernández⁹, L. Martinez-Costa¹⁰, Inmaculada Calvo¹¹, Antonio Atanes-Sandoval¹², Luis Linares¹³, Consuelo Modesto¹⁴, Elena Aurrecochea¹⁵, Miguel Cordero-Coma¹⁶, Lucia C. Domínguez-Casas¹, Carlos Fernández-Díaz¹, Miguel Angel González-Gay¹ and Ricardo Blanco¹⁷, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Ophtalmology, Hospital Clinic, Barcelona, Spain, ³Ophthalmology, Hospital Clinic de Barcelona,, Barcelona, Spain, ⁴Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁵Rheumatology, Hospital General Universitario de Valencia, Valencia, Spain, ⁶Rheumatology, Hospital Dr. Peset., Valencia, Spain, ⁷Ophthalmology Department, Hospital Clínico San Carlos, Madrid, Spain, ⁸Rheumatology, Hospital Regional Universitario (Carlos Haya). Málaga. Spain., Málaga, Spain, ⁹Ophthalmology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ¹⁰Hospital Dr. Peset., Valencia, Spain, ¹¹Pediatric Rheumatology, Hospital Univ. La Fe, Valencia, Spain, ¹²Rheumatology, Complejo Hospitalario Universitario de La Coruña, La Coruña, Spain, ¹³Rheumatologist, hospital de la Arrixaca, MURCIA, Spain, ¹⁴Hospital Valle de Hebron, Barcelona, Spain, ¹⁵Rheumatology, Hospital de Sierrallana, Torrelavega, Spain, ¹⁶Departament of Ophthalmology, Hospital de León, León, Spain, ¹⁷Rheumatology Department. Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Our objective was to evaluate the efficacy and safety of Tocilizumab (TCZ) in a series of patients with refractory CME. Methods: A Multicenter…
Abstract Number: 1337 • 2016 ACR/ARHP Annual Meeting
Effectiveness of Certolizumab Pegol in Patients with Uveitis Refractory to Other Tumor Necrosis Factor Inhibitors. Report of 22 Cases
M. Victoria Hernández¹, Marina Mesquida², Victor Llorens², Maite Sainz de la Maza², Gerard Espinosa³, Ricardo Blanco⁴, Vanesa Calvo⁴, Olga Maiz⁵, Ana Blanco⁶, Juan Ramon De Dios⁷, Pilar Ahijado-Guzman⁸, Enrique Judez⁹, Patricia Tejón¹⁰, M Soledad Peña¹¹, Raimon Sanmarti¹ and Alfredo Adan¹², ¹Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Ophthalmology Department. Hospital Clínic de Barcelona, Barcelona, Spain, ³Autoimmune Diseases Department. Hospital Clínic de Barcelona, Barcelona, Spain, ⁴Rheumatology Department. Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Rheumatology Department. Donostia University Hospital, San Sebastian, Spain, ⁶Ophthalmology Department. Donostia University Hospital, Donostia, Spain, ⁷Rheumatology, Hospital Universitario de Araba, Vitoria, Spain, ⁸Avda. Reyes Catolicos, 21, Rheumatology Department. Hospital Infanta Elena, Valdemoro, Madrid, Spain, ⁹Rheumatology Department. Hospital de Albacete, Albacete, Spain, ¹⁰Rheumatology Department. Hospital Universitario General de Castellón, Castellon, Spain, ¹¹Ophtalmology Dpt. Hospital Universitario General de Castellón, Castellon, Spain, ¹²Ophthalmology, Ophthalmology Department. Hospital Clínic de Barcelona, Barcelona, Spain
Background/Purpose: Refractory uveitis may requiere the use of biological therapy, especially tumour necrosis factors inhibitors (TNFi), being the most currently used infliximab and adalimumab. However,…
Abstract Number: 1338 • 2016 ACR/ARHP Annual Meeting
Use of Subcutaneous Golimumab in Autoimmune Inner Ear Disease
Deeba Minhas¹, Michele Gandolfi², Jennifer Derebery³, Eric Wilkinson³ and Mariko Ishimori¹, ¹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ²Otology, House Clinic, Los Angeles, CA, ³House Clinic, Los Angeles, CA
Background/Purpose: Autoimmune Inner Ear Disease (AIED) is characterized by rapidly progressive sensorineural hearing loss accompanied by tinnitus, with or without vertigo, which may progress to…
Abstract Number: 1339 • 2016 ACR/ARHP Annual Meeting
Rheumatic Immune Related Adverse Events of Checkpoint Therapy for Cancer: Case Series of a New Nosologic Entity
Cassandra Calabrese¹, Apostolos Kontzias¹, Vamsidhar Velcheti² and Leonard H. Calabrese¹, ¹Rheumatic & Immunologic Disease, Cleveland Clinic, Cleveland, OH, ²Hematology and Oncology, Cleveland Clinic, Cleveland, OH
Background/Purpose: The introduction of immunotherapy with biologic agents targeting immunologic checkpoints (i.e. CTLA4 and PD-1/PDL-1) have yielded impressive gains for cancer patients. These agents…
Abstract Number: 1340 • 2016 ACR/ARHP Annual Meeting
Type and Frequency of Immune-Related Adverse Reactions in Patients Treated with Pembrolizumab (Keytruda), a Monoclonal Antibody Directed Against PD-1, in Advanced Melanoma at a Single Institution
Olga Pinkston¹, Florentina Berianu¹ and Benjamin Wang², ¹Rheumatology, Mayo Clinic, Jacksonville, FL, ²Division of Rheumatology, Mayo Clinic, Jacksonville, FL
Background/Purpose: Although immune checkpoint inhibitors improve survival in patients with melanoma and other cancers, the alterations to the immune system induced by these medications can…
Abstract Number: 1341 • 2016 ACR/ARHP Annual Meeting
Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Literature Review
Laura Cappelli¹, Anna Kristina Gutierrez², Ami A. Shah³ and Clifton Bingham III⁴, ¹Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Johns Hopkins University, Baltimore, MD
Rheumatic and Musculoskeletal Immune-Related Adverse Events due to Immune Checkpoint Inhibitors: A Systematic Literature Review Background/Purpose: Immune checkpoint inhibitors (ICI) are effective treatments for advanced…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].